Listed by the USPTO as RAMACHANDRAN, UMAMAHESWARI
Tech Center 1600 • Art Units: 1617 1627 1629
This examiner grants 55% of resolved cases
RAMACHANDRAN, UMAMAHESWARI has resolved 1193 cases in Tech Center 1600 and Art Unit 1617. The allowance rate is 54.8%, while the 53.7% interview lift is nearly as large as the allowance rate itself. The median time to allowance is 1128 days, so prosecution planning should account for a substantial interval before allowance.
The listed company experience includes Janssen Pharmaceuticals Inc., The Johns Hopkins University, and Nestlé S.A. The listed firms are Jones Day, THE FIRM OF HUESCHEN AND SAGE, and ARENTFOX SCHIFF LLP - Los Angeles. These matters suggest that interview preparation may warrant particular attention, while claim amendments and evidence should be developed with the examiner's allowance pattern in mind. The large resolved-case base gives the metrics a broad historical foundation.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18012446 | USE OF N-PHENYLACETAMIDES HAVING P2X4 RECEPTOR ANTAGONISTIC ACTIVITY FOR TREATING CERTIAN OCULAR DISORDERS | Non-Final OA | The Johns Hopkins University |
| 17596784 | COMPOSITIONS AND METHODS TO POTENTIATE MUSCULOSKELETAL EFFECT OF ONE OR MORE ANABOLIC AMINO ACIDS | Non-Final OA | SOCIETE DES PRODUITS NESTLE S.A. |
| 18780629 | METHODS FOR TREATING ATTENTION-DEFICIT/HYPERACTIVITY DISORDER | Non-Final OA | SK BIOPHARMACEUTICALS CO., LTD. |
| 18926122 | COMPOSITIONS CONTAINING A NON-CAFFEINE STIMULANT OR NOOTROPIC AND BETA-HYDROXYBUTYRATE OR PRECURSOR FOR INCREASING NEUROLOGICAL AND PHYSIOLOGICAL PERFORMANCE | Final Rejection | AXCESS GLOBAL SCIENCES, LLC |
| 18842004 | (3S,4R)-3-AMINO-4-(DIFLUOROMETHYL)CYCLOPENT-1-ENE-1-CARBOXYLIC ACID AND RELATED COMPOUNDS AS SELECTIVE INACTIVATORS OF ORNITHINE AMINOTRANSFERASE | Non-Final OA | Northwestern University |
| 18656920 | COMPOSITION COMPRISING TETRACYCLIC COMPOUND | Non-Final OA | CHUGAI SEIYAKU KABUSHIKI KAISHA |
| 18715132 | Tellurium-containing compounds and the use of treating bacterial infections thereof | Non-Final OA | Kaohsiung Medical University |
| 18787713 | COMBINATIONS COMPRISING POSITIVE ALLOSTERIC MODULATORS OR ORTHOSTERIC AGONISTS OF METABOTROPIC GLUTAMATERGIC RECEPTOR SUBTYPE 2 AND THEIR USE | Non-Final OA | JANSSEN PHARMACEUTICA NV |
| 18754070 | TREATMENT OF CIRCADIAN RHYTHM DISORDERS | Non-Final OA | Vanda Pharmaceuticals Inc. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy54.8% of resolved applications examined by Umamaheswari Ramachandran were allowed (1,193 resolved cases), compared with 34.1% across Art Unit 1617 over the last five years.
This examiner's interview lift is +53.7 percentage points: the difference in allowance rate between resolved applications that had an examiner interview and those that did not.
Applications allowed by Umamaheswari Ramachandran took 1,128 days on average from filing to allowance.
Umamaheswari Ramachandran examines applications in Art Unit 1617 in Tech Center 1600 (Biotechnology & Pharmaceuticals).
